{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:41:21Z","timestamp":1787164881992,"version":"build-2736575974"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To evaluate the analgesic efficacy of high-dose celecoxib in the treatment of moderate to extreme pain and inflammation associated with acute gouty arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>A multinational, randomized, double-blind, double-dummy, active-controlled trial was done with patients (aged \u2265 18 years) with acute gouty monoarthritis or oligoarthritis (onset of pain \u2264 48 h before enrollment). Patients were treated for 8 days with 1 week followup and were randomized 1:1:1:1 to receive celecoxib 50 mg bid, celecoxib 400 mg (followed by 200 mg later on Day 1 and then 200 mg bid for 7 days), celecoxib 800 mg (followed by 400 mg later on Day 1 and then 400 mg bid for 7 days), or indomethacin 50 mg tid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of 443 patients screened, 402 were randomized and 400 received treatment. Baseline demographics were comparable among treatments. Patients receiving high-dose celecoxib (800\/400 mg) experienced a significantly greater reduction in pain intensity on Day 2 compared with low-dose celecoxib 50 mg bid [least squares (LS) mean difference \u22120.46; p = 0.0014]. For high-dose celecoxib 800\/400 mg, the change in pain scores from baseline to Day 2 was comparable with indomethacin 50 mg tid (LS mean difference 0.11; p = 0.4331). There were significant differences in adverse events when the combined celecoxib groups (29.5%) were compared with patients taking indomethacin (43.1%; p = 0.0116). There was no change in median serum creatinine levels for any treatment. There were more discontinuations due to adverse events (8.8% vs 3%; p = 0.0147) with indomethacin than with the combined celecoxib groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>High-dose celecoxib (800\/400 mg) was significantly more effective than low-dose celecoxib (50 mg bid) and comparable to indomethacin in the treatment of moderate to extreme pain in patients with acute gouty arthritis. Further, celecoxib was well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.110916","type":"journal-article","created":{"date-parts":[[2012,8,2]],"date-time":"2012-08-02T01:29:34Z","timestamp":1343870974000},"page":"1859-1866","source":"Crossref","is-referenced-by-count":51,"title":["Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial"],"prefix":"10.3899","volume":"39","author":[{"given":"H. RALPH","family":"SCHUMACHER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MANUELA F.","family":"BERGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JULIE","family":"LI-YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FERNANDO","family":"PEREZ-RUIZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RUB\u00c9N","family":"BURGOS-VARGAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHUNMING","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"2018112909283417000_39.9.1859.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02188.x"},{"key":"2018112909283417000_39.9.1859.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep086"},{"key":"2018112909283417000_39.9.1859.3","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181896c35"},{"key":"2018112909283417000_39.9.1859.4","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181896921"},{"key":"2018112909283417000_39.9.1859.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"2018112909283417000_39.9.1859.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"2018112909283417000_39.9.1859.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel071"},{"key":"2018112909283417000_39.9.1859.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1315"},{"key":"2018112909283417000_39.9.1859.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055251"},{"key":"2018112909283417000_39.9.1859.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"2018112909283417000_39.9.1859.11","unstructured":"New Zealand Rheumatism Association consensus statement on the use of colchicine in the treatment of gout. [Internet. Accessed May 29, 2012.] Available from: http:\/\/www.rheumatology.org.nz\/position_statement.cfm"},{"key":"2018112909283417000_39.9.1859.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780220420"},{"key":"2018112909283417000_39.9.1859.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(95)70037-4"},{"key":"2018112909283417000_39.9.1859.14","doi-asserted-by":"publisher","DOI":"10.1185\/03007999109111513"},{"key":"2018112909283417000_39.9.1859.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem090"},{"issue":"Suppl","key":"2018112909283417000_39.9.1859.16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009747809095668","article-title":"Treatment of acute gouty arthritis with proquazone and indomethacin: A comparative, double-blind trial","volume":"21","author":"Ruotsi","year":"1978","journal-title":"Scand J Rheumatol"},{"key":"2018112909283417000_39.9.1859.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91843-0"},{"key":"2018112909283417000_39.9.1859.18","unstructured":"Singh G Rosen Ramey D . NSAID induced gastrointestinal complications: The ARAMIS perspective \u2013 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998 May;51:8\u201316."},{"key":"2018112909283417000_39.9.1859.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1488"},{"key":"2018112909283417000_39.9.1859.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20007"},{"key":"2018112909283417000_39.9.1859.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.619"},{"key":"2018112909283417000_39.9.1859.22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01219.x"},{"key":"2018112909283417000_39.9.1859.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"2018112909283417000_39.9.1859.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.008"},{"key":"2018112909283417000_39.9.1859.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"2018112909283417000_39.9.1859.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.004671"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:18:23Z","timestamp":1543497503000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,9,1]]},"published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.3899\/jrheum.110916"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110916","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954642.793462571","asserted-by":"object"}]},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}